Idiopathic Pulmonary Fibrosis: A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.Bleomycin: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.Lung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.Bronchoalveolar Lavage Fluid: Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.Alveolitis, Extrinsic Allergic: A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis.Idiopathic Interstitial Pneumonias: A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.Sarcoidosis, Pulmonary: Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)Pulmonary Alveoli: Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.Respiratory Function Tests: Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.Lung Transplantation: The transference of either one or both of the lungs from one human or animal to another.Fibroblasts: Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.Myofibroblasts: Spindle-shaped cells with characteristic CONTRACTILE PROTEINS and structures that contribute to the WOUND HEALING process. They occur in GRANULATION TISSUE and also in pathological processes such as FIBROSIS.Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.Pyridones: Pyridine derivatives with one or more keto groups on the ring.Cryptogenic Organizing Pneumonia: An interstitial lung disease of unknown etiology, occurring between 21-80 years of age. It is characterized by a dramatic onset of a "pneumonia-like" illness with cough, fever, malaise, fatigue, and weight loss. Pathological features include prominent interstitial inflammation without collagen fibrosis, diffuse fibroblastic foci, and no microscopic honeycomb change. There is excessive proliferation of granulation tissue within small airways and alveolar ducts.Bronchoalveolar Lavage: Washing out of the lungs with saline or mucolytic agents for diagnostic or therapeutic purposes. It is very useful in the diagnosis of diffuse pulmonary infiltrates in immunosuppressed patients.Pulmonary Diffusing Capacity: The amount of a gas taken up, by the pulmonary capillary blood from the alveolar gas, per minute per unit of average pressure of the gradient of the gas across the BLOOD-AIR BARRIER.Pneumocytes: Epithelial cells that line the PULMONARY ALVEOLI.Pulmonary Surfactant-Associated Protein C: A pulmonary surfactant associated protein that plays a role in alveolar stability by lowering the surface tension at the air-liquid interface. It is a membrane-bound protein that constitutes 1-2% of the pulmonary surfactant mass. Pulmonary surfactant-associated protein C is one of the most hydrophobic peptides yet isolated and contains an alpha-helical domain with a central poly-valine segment that binds to phospholipid bilayers.Respiratory System Agents: Drugs used for their effects on the respiratory system.Vital Capacity: The volume of air that is exhaled by a maximal expiration following a maximal inspiration.Sarcoidosis: An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.Collagen Diseases: Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)Respiratory Aspiration: Inhaling liquid or solids, such as stomach contents, into the RESPIRATORY TRACT. When this causes severe lung damage, it is called ASPIRATION PNEUMONIA.Transforming Growth Factor beta1: A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.Total Lung Capacity: The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: VITAL CAPACITY plus RESIDUAL VOLUME; INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual capacity; or tidal volume plus inspiratory reserve volume plus EXPIRATORY RESERVE VOLUME plus residual volume.Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.Collagen: A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH).Mucin-5B: A gel-forming mucin that is predominantly expressed by submucosal glands of airway tissues and the SUBLINGUAL GLAND. It is one of the principal components of high molecular weight salivary mucin.Pulmonary Surfactant-Associated Protein A: An abundant pulmonary surfactant-associated protein that binds to a variety of lung pathogens, resulting in their opsinization. It also stimulates MACROPHAGES to undergo PHAGOCYTOSIS of microorganisms. Surfactant protein A contains a N-terminal collagen-like domain and a C-terminal lectin domain that are characteristic of members of the collectin family of proteins.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Lung Diseases: Pathological processes involving any part of the LUNG.Dyspnea: Difficult or labored breathing.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Pulmonary Emphysema: Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.Macrophages, Alveolar: Round, granular, mononuclear phagocytes found in the alveoli of the lungs. They ingest small inhaled particles resulting in degradation and presentation of the antigen to immunocompetent cells.Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.Respiratory Mucosa: The mucous membrane lining the RESPIRATORY TRACT, including the NASAL CAVITY; the LARYNX; the TRACHEA; and the BRONCHI tree. The respiratory mucosa consists of various types of epithelial cells ranging from ciliated columnar to simple squamous, mucous GOBLET CELLS, and glands containing both mucous and serous cells.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Mice, Inbred C57BLPulmonary Surfactant-Associated Protein D: An abundant pulmonary surfactant-associated protein that binds to a variety of lung pathogens and enhances their opsinization and killing by phagocytic cells. Surfactant protein D contains a N-terminal collagen-like domain and a C-terminal lectin domain that are characteristic of members of the collectin family of proteins.Lung Injury: Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Primary Graft Dysfunction: A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.HSP47 Heat-Shock Proteins: Basic glycoprotein members of the SERPIN SUPERFAMILY that function as COLLAGEN-specific MOLECULAR CHAPERONES in the ENDOPLASMIC RETICULUM.Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Epithelial Cells: Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Collagen Type I: The most common form of fibrillar collagen. It is a major constituent of bone (BONE AND BONES) and SKIN and consists of a heterotrimer of two alpha1(I) and one alpha2(I) chains.Diagnostic Techniques, Respiratory System: Methods and procedures for the diagnosis of diseases of the respiratory tract or its organs. It includes RESPIRATORY FUNCTION TESTS.Hemoperfusion: Removal of toxins or metabolites from the circulation by the passing of blood, within a suitable extracorporeal circuit, over semipermeable microcapsules containing adsorbents (e.g., activated charcoal) or enzymes, other enzyme preparations (e.g., gel-entrapped microsomes, membrane-free enzymes bound to artificial carriers), or other adsorbents (e.g., various resins, albumin-conjugated agarose).Pulmonary Medicine: A subspecialty of internal medicine concerned with the study of the RESPIRATORY SYSTEM. It is especially concerned with diagnosis and treatment of diseases and defects of the lungs and bronchial tree.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Therapeutic Irrigation: The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis.Cystic Fibrosis Transmembrane Conductance Regulator: A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Pneumonia: Infection of the lung often accompanied by inflammation.Epithelial-Mesenchymal Transition: Phenotypic changes of EPITHELIAL CELLS to MESENCHYME type, which increase cell mobility critical in many developmental processes such as NEURAL TUBE development. NEOPLASM METASTASIS and DISEASE PROGRESSION may also induce this transition.Expectorants: Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.Acetylcysteine: The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.Endomyocardial Fibrosis: A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).Emphysema: A pathological accumulation of air in tissues or organs.Pulmonary Gas Exchange: The exchange of OXYGEN and CARBON DIOXIDE between alveolar air and pulmonary capillary blood that occurs across the BLOOD-AIR BARRIER.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Telomerase: An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Retroperitoneal Fibrosis: A slowly progressive condition of unknown etiology, characterized by deposition of fibrous tissue in the retroperitoneal space compressing the ureters, great vessels, bile duct, and other structures. When associated with abdominal aortic aneurysm, it may be called chronic periaortitis or inflammatory perianeurysmal fibrosis.Peplomycin: An antineoplastic agent derived from BLEOMYCIN.Matrix Metalloproteinase 7: The smallest member of the MATRIX METALLOPROTEINASES. It plays a role in tumor progression.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Scoliosis: An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)Telomere Shortening: The loss of some TELOMERE sequence during DNA REPLICATION of the first several base pairs of a linear DNA molecule; or from DNA DAMAGE. Cells have various mechanisms to restore length (TELOMERE HOMEOSTASIS.) Telomere shortening is involved in the progression of CELL AGING.Proton Therapy: The use of an external beam of PROTONS as radiotherapy.Acute Disease: Disease having a short and relatively severe course.Ciliary Neurotrophic Factor Receptor alpha Subunit: A ciliary neurotrophic factor receptor subunit. It is anchored to the cell surface via GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE and has specificity for binding to CILIARY NEUROTROPHIC FACTOR. It lacks signal transducing domains which are found on the other two subunits of the receptor.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Collagen Type V: A fibrillar collagen found widely distributed as a minor component in tissues that contain COLLAGEN TYPE I and COLLAGEN TYPE III. It is a heterotrimeric molecule composed of alpha1(V), alpha2(V) and alpha3(V) subunits. Several forms of collagen type V exist depending upon the composition of the subunits that form the trimer.Anti-Inflammatory Agents: Substances that reduce or suppress INFLAMMATION.Connective Tissue Growth Factor: A CCN protein family member that regulates a variety of extracellular functions including CELL ADHESION; CELL MIGRATION; and EXTRACELLULAR MATRIX synthesis. It is found in hypertrophic CHONDROCYTES where it may play a role in CHONDROGENESIS and endochondral ossification.Exercise Test: Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used.Dyskeratosis Congenita: A predominantly X-linked recessive syndrome characterized by a triad of reticular skin pigmentation, nail dystrophy and leukoplakia of mucous membranes. Oral and dental abnormalities may also be present. Complications are a predisposition to malignancy and bone marrow involvement with pancytopenia. (from Int J Paediatr Dent 2000 Dec;10(4):328-34) The X-linked form is also known as Zinsser-Cole-Engman syndrome and involves the gene which encodes a highly conserved protein called dyskerin.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Arthritis, Juvenile: Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Extracellular Matrix: A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere.Actins: Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle.Smad3 Protein: A receptor-regulated smad protein that undergoes PHOSPHORYLATION by ACTIVIN RECEPTORS, TYPE I. Activated Smad3 can bind directly to DNA, and it regulates TRANSFORMING GROWTH FACTOR BETA and ACTIVIN signaling.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Purpura, Thrombocytopenic, Idiopathic: Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Forced Expiratory Volume: Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Walking: An activity in which the body advances at a slow to moderate pace by moving the feet in a coordinated fashion. This includes recreational walking, walking for fitness, and competitive race-walking.Bird Fancier's Lung: A form of alveolitis or pneumonitis due to an acquired hypersensitivity to inhaled avian antigens, usually proteins in the dust of bird feathers and droppings.Lung Volume Measurements: Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Smoking: Inhaling and exhaling the smoke of burning TOBACCO.Epithelium: One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.Torque teno virus: A species of non-enveloped DNA virus in the genus ANELLOVIRUS, associated with BLOOD TRANSFUSIONS; and HEPATITIS. However, no etiological role has been found for TTV in hepatitis.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Airway Remodeling: The structural changes in the number, mass, size and/or composition of the airway tissues.Hermanski-Pudlak Syndrome: Syndrome characterized by the triad of oculocutaneous albinism (ALBINISM, OCULOCUTANEOUS); PLATELET STORAGE POOL DEFICIENCY; and lysosomal accumulation of ceroid lipofuscin.DNA Virus InfectionsProspective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Leukocyte Count: The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.Gene Expression Regulation: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.Asbestosis: A form of pneumoconiosis caused by inhalation of asbestos fibers which elicit potent inflammatory responses in the parenchyma of the lung. The disease is characterized by interstitial fibrosis of the lung, varying from scattered sites to extensive scarring of the alveolar interstitium.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Dimitroulis, IA (September 2014). "Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis". Respiratory ... Nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). It has been shown to slow down decrease in forced ... Boehringer is using the brand name Ofev for marketing nintedanib for idiopathic pulmonary fibrosis and Vargatef for marking the ... Ahluwalia, N; Shea, BS; Tager, AM (15 October 2014). "New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein ...
cited by Michaelson JE, Aguayo SM, Roman J. Idiopathic Pulmonary Fibrosis: A Practical Approach for Diagnosis and Management. ... In this case, it is termed "idiopathic". Most idiopathic cases are diagnosed as idiopathic pulmonary fibrosis. This is a ... There is no known cure for the scars and damage in the lung due to pulmonary fibrosis. Symptoms of pulmonary fibrosis are ... Misdiagnosis is common because, while overall pulmonary fibrosis is not rare, each individual type of pulmonary fibrosis is ...
Idiopathic pulmonary fibrosis
2004). "Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?". Am J Respir Crit ... 2011). "Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis". Respir Med. 105 (12): 1902 ... The number of published studies on the role of pulmonary rehabilitation in idiopathic pulmonary fibrosis is small, but most of ... Kenn, K; Gloeckl, R; Behr, J (2013). "Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis-a review". ...
Idiopathic interstitial pneumonia
Katzenstein AL, Myers JL (1998). "Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification". Am. J. ... October 2004). "Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?". Am. J. ... Practical Pulmonary Pathology: A Diagnostic Approach. Elsevier Inc. 2005. ISBN 978-0-443-06631-3. American Thoracic, Society; ... Idiopathic interstitial pneumonia (IIP), or noninfectious pneumonia are a class of diffuse lung diseases. These diseases ...
Usual interstitial pneumonia
Pneumoconiosis Silicosis Asbestosis Idiopathic pulmonary fibrosis Pulmonary fibrosis Emphysema Travis WD, King TE, Bateman ED, ... Leslie, Kevin O; Wick, Mark R. (2005). Practical pulmonary pathology: a diagnostic approach. Edinburgh: Churchill Livingstone. ... "idiopathic", the clinical term for UIP of unknown cause is idiopathic pulmonary fibrosis (IPF). Examples of known causes of UIP ... In case of idiopathic pulmonary fibrosis, certain medications like pirfenidone can help slow the progression. Lastly, lung ...
... idiopathic pulmonary fibrosis pattern' on HRCT scan - Experience from a tertiary care center of North India". Lung India. 32 (5 ... Any approach to lung biopsy risks causing a pneumothorax. Careful technique can limit this risk, which ranges from less than 1 ... ISBN 978-1-4511-5278-4. Mostafa M. Fraig (21 April 2015). Diagnosis of Small Lung Biopsy: An Integrated Approach. Springer. ...
Induced stem cells
Chronic lung diseases such as idiopathic pulmonary fibrosis and cystic fibrosis or chronic obstructive pulmonary disease and ... A different approach to CRC is to inhibit CD47-a membrane protein that is the thrombospondin-1 receptor. Loss of CD47 permits ... An analogous approach was used to induce activation of the endogenous Brn2, Ascl1, and Myt1l genes to convert mouse embryonic ... This chemical reprogramming approach, after further optimization, may offer an easy way to provide the cues that induce heart ...
Jerry Norman (sinologist)
... idiopathic usual interstitial pneumonia (i.e. idiopathic pulmonary fibrosis), are very poor and the treatments of little help. ... Mukhopadhyay S, Gal AA (2010). "Granulomatous lung disease: an approach to the differential diagnosis". Archives of Pathology ... Pulmonary function tests show reduced diffusion capacity of lungs for carbon monoxide (DLCO). Many patients have hypoxemia at ... When fibrosis develops in chronic hypersensitivity pneumonitis, the differential diagnosis in lung biopsies includes the ...
Interstitial lung disease
Prolonged ILD may result in pulmonary fibrosis, but this is not always the case. Idiopathic pulmonary fibrosis is interstitial ... doi: 10.1186/s13023-015-0339-1. Ryu, JH; Olson, EJ; Midthun, DE; Swensen, SJ (Nov 2002). "Diagnostic approach to the patient ... Lower lung predominance Idiopathic pulmonary fibrosis, pulmonary fibrosis associated with connective tissue diseases, ... Pulmonary edema Chronic: Idiopathic pulmonary fibrosis, connective tissue associated interstitial lung diseases, asbestosis, ...
Terence T. Evans
... is upregulated in cases of liver fibrosis, renal fibrosis, and idiopathic pulmonary fibrosis (IPF). In several ... One approach to cancers with high galectin-3 expression is to use small molecule inhibition of galectin-3 to enhance treatment ... Galectin-3 is upregulated in patients with idiopathic pulmonary fibrosis. The cells that receive galectin-3 stimulation ( ... specifically idiopathic pulmonary fibrosis. Galectin Therapeutics in the United States is also using galectins for their ...
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012). "Prednisone, Azathioprine, and N-Acetylcysteine for ... Sami, Naveed (2016). Autoimmune Bullous Diseases: Approach and Management. Springer. p. 83. ISBN 9783319267289. Archived from ... A widely used therapy for idiopathic pulmonary fibrosis was azathioprine in combination with prednisone and N-acetylcysteine. A ... Pulmonary Fibrosis". N Engl J Med. 366: 1968-1977. doi:10.1056/NEJMoa1113354. PMC 3422642 . PMID 22607134. Jasek, W, ed. (2007 ...
He had idiopathic pulmonary fibrosis, for which he received a lung transplant in December 2003. He died the following month in ... Calisher and emerging infectious disease specialist C. J. Peters highlighted his multidisciplinary approach, stating that "He ... Epidemiologist and emerging infectious disease specialist Stephen S. Morse considered Shope to exemplify the approach of " ...
The differential diagnosis includes idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis, and others ... The Health Effects of Asbestos: An Evidence-based Approach. 2015. ISBN 9781498728409. Warheit D. B.; Hill L. H.; George G.; ... Conversely, interstitial pulmonary fibrosis in the absence of asbestos bodies is most likely not asbestosis. Asbestos bodies in ... CT or high-resolution CT (HRCT) are more sensitive than plain radiography at detecting pulmonary fibrosis (as well as any ...
Granulomatous lung diseases Tuberculosis Fungal infections Granulomatosis with polyangiitis Idiopathic pulmonary fibrosis ... it is still considered to be an accepted approach to treatment in any stage of disease. People with early stages of disease, ... In later stages hilar lymphadenopathy, intersitial pulmonary fibrosis and pleural thickening. Berylliosis is an occupational ... Eventually, the final outcome is fibrosis of the lung. Several studies have shown that there is a genetic component to ...
Other possible pulmonary manifestations of Marfan syndrome include sleep apnea and idiopathic obstructive lung disease. ... As an alternative approach, custom-built supports for the aortic root are also being used. During pregnancy, even in the ... apical fibrosis and congenital malformations such as middle lobe hypoplasia. Dural ectasia, the weakening of the connective ... Pulmonary symptoms are not a major feature of Marfan syndrome, but spontaneous pneumothorax is common. In spontaneous ...
Several approaches to taking tissue samples are available Insertion of a needle through the skin on the chest to remove a small ... Fishman's Pulmonary Diseases and Disorders. New York: McGraw-Hill, Health Professions Division, 1997. Peters RR, Saleh TF, Lora ... Some cases of pleuritic chest pain are idiopathic, which means that the exact cause cannot be determined. A diagnosis of ... Inflammatory bowel disease Lung cancer and lymphoma Other lung diseases like cystic fibrosis, sarcoidosis, asbestosis, ...
Shortness of breath
... pulmonary embolism, or pneumothorax. Patients with COPD and idiopathic pulmonary fibrosis (IPF) have a gradual progression of ... The initial approach to evaluation begins by assessment of the airway, breathing, and circulation followed by a medical history ... Pulmonary embolism. Pulmonary embolism classically presents with an acute onset of shortness of breath. Other ... Chronic obstructive pulmonary disease. People with chronic obstructive pulmonary disease (COPD), most commonly emphysema ...
March 2010). "Cystic Fibrosis Pulmonary Guidelines: Pulmonary Complications: Hemoptysis and Pneumthorax". Am J Respir Crit Care ... "Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis". N. Engl. J. Med. 339 (10): 653-8. doi: ... One approach is to develop drugs that get the ribosome to overcome the stop codon and synthesize a full-length CFTR protein. ... The name 'cystic fibrosis' refers to the characteristic fibrosis and cysts that form within the pancreas. Play media The main ...
Pulmonary toxicity *interstitial pneumonitis. *bronchiolitis obliterans with organizing pneumonia (BOOP). *pulmonary fibrosis ... The most promising approach to combating resistance is likely to be combination therapy. Commencing treatment with a number of ... and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that ...
These cases are associated with hypertension in the pulmonary arteries. The bone marrow in a typical case is hypercellular and ... A bone marrow biopsy will reveal collagen fibrosis, replacing the marrow that would normally occupy the space. The one known ... The term myelofibrosis alone usually refers to primary myelofibrosis (PMF), also known as chronic idiopathic myelofibrosis ( ... curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks. Other treatment ...
A bone marrow biopsy will reveal collagen fibrosis, replacing the marrow that would normally occupy the space. ... The underlying cause of PMF is unknown (idiopathic disease). There is an association between mutations to the JAK2, CALR, or ... These cases are associated with hypertension in the pulmonary arteries.. The bone marrow in a typical case is hypercellular ... The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks. ...
კისტური ფიბროზი - ვიკიპედია
March 2010). "Cystic Fibrosis Pulmonary Guidelines: Pulmonary Complications: Hemoptysis and Pneumothorax". Am J Respir Crit ... "Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis". N. Engl. J. Med. 339 (10): 653-8. . PMID ... "New therapeutic approaches to Mendelian disorders". N. Engl. J. Med. 363 (9): 852-63. . PMID 20818846. http://www.nejm.org/doi ... "Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease 11 (11): ...
Marik, PE (May 2011). "Pulmonary aspiration syndromes". Current Opinion in Pulmonary Medicine. 17 (3): 148-54. doi:10.1097/MCP. ... Idiopathic interstitial pneumonia or noninfectious pneumonia is a class of diffuse lung diseases. They include diffuse alveolar ... Risk factors include other lung diseases such as cystic fibrosis, COPD, and asthma, diabetes, heart failure, a history of ... Francis Waldvogel (1999). Clinical infectious diseases : a practical approach. New York, NY [u.a.]: Oxford Univ. Press. p. 833 ...
Ryu, J. H. (Mar 2006). "Classification and approach to bronchiolar diseases". Current Opinion in Pulmonary Medicine. 12 (2): ... and obstructive respiratory functional impairment is found on pulmonary function testing. Cystic fibrosis, like DPB, causes ... DPB is idiopathic, which means an exact physiological, environmental, or pathogenic cause of the disease is unknown. However, ... and can eventually lead to pulmonary hypertension (high blood pressure in the pulmonary vein and artery) and cor pulmonale ( ...
German Respiratory Society
"Guideline for diagnosis and management of idiopathic pulmonary fibrosis") has also appeared in 2013. In addition to position ... Despite different approaches, the prevalence of the disease followed a similar pattern in both German states. Whereas the ... pneumonia and pulmonary hypertension) and new techniques in pulmonary function diagnostics and endoscopy, improvements in ... The key principle was not so much the promotion of specialized research activities as an interdisciplinary approach to "gather ...
Combined pulmonary fibrosis and emphysema (CPFE) is a rare syndrome that shows upper-lobe emphysema, together with lower-lobe ... McCormick, Michael E.; Bawa, Gurneet; Shah, Rahul K. (2013). "Idiopathic recurrent pneumoparotitis". American Journal of ... "GOLD 2017 recommendations for COPD patients: toward a more personalized approach" (PDF). COPD Research and Practice. 3. doi ... Pulmonary interstitial emphysema. Main article: Pulmonary interstitial emphysema. Pulmonary interstitial emphysema (PIE) ...
Primary/idiopathic. 85% of MGN cases are classified as primary membranous glomerulonephritis-that is to say, the cause of ... membranous nephropathy is known to predispose affected individuals to develop blood clots such as pulmonary emboli. Membranous ... "Membranous nephropathy in children: clinical presentation and therapeutic approach". Pediatric Nephrology. 25 (8): 1419-28. ... For treatment of idiopathic membranous nephropathy, the treatment options include immunosuppressive drugs and non-specific anti ...
Chronic obstructive pulmonary disease
fibrosis). External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. ... Gompelmann D, Eberhardt R, Herth FJ (August 2015). "Novel Endoscopic Approaches to Treating Chronic Obstructive Pulmonary ... Wikimedia Commons has media related to Chronic obstructive pulmonary disease.. *Chronic obstructive pulmonary disease at Curlie ... "Chronic obstructive pulmonary disease (COPD)". WHO. Retrieved 5 June 2019. Chronic Obstructive Pulmonary Disease (COPD) is not ...
Typical nonpharmacologic approaches to the management of COPD including bronchitis may include pulmonary rehabilitation, lung ... fibrosis). External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. ... "International Journal of Chronic Obstructive Pulmonary Disease. 6: 413-421. doi:10.2147/COPD.S10770. PMC 3157944. PMID 21857781 ... Chronic Obstructive Pulmonary Disease Harrison's Principles of Internal Medicine (17th ed.). New York: McGraw-Hill. ISBN 978-0- ...
Exposure to carbon monoxide or polluted ozone exposure can also lead to cardiac defects of the ventrical septal, pulmonary ... Syphilis causes congenital deafness, mental retardation, and diffuse fibrosis in organs, such as the liver and lungs, if the ... systemic-evolutionary approach). In: Mathematical treatment of medical-biological information. M., Nauka, p. 170-181. ... Idiopathic. *List of congenital disorders. *List of ICD-9 codes 740-759: Congenital anomalies ...
Idiopathic pulmonary fibrosis. *Sarcoidosis. Obstructive or. restrictive. Pneumonia/. pneumonitis. By pathogen. *Viral ... for detection of exercise-induced bronchoconstriction in athletes and are also not a recommended first-line approach in the ... fibrosis). External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. ... 2008). "Pulmonary gas exchange response to exercise- and mannitol-induced bronchoconstriction in mild asthma". J Appl Physiol. ...
ಪಲ್ಮನರಿ ಎಂಬಾಲಿಸಮ್ (ಶ್ವಾಸಕೋಶದ ಧಮನಿಬಂಧ) - ವಿಕಿಪೀಡಿಯ
2007). "Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary ... Bauxite fibrosis. Berylliosis. Caplan's syndrome. Chalicosis. Coalworker's pneumoconiosis. Siderosis. Silicosis. Talcosis. ... Augustinos P, Ouriel K (2004). "Invasive approaches to treatment of venous thromboembolism". Circulation. 110 (9 Suppl 1): I27- ... Goldhaber SZ (2004). "Pulmonary embolism". Lancet. 363 (9417): 1295-305. doi:10.1016/S0140-6736(04)16004-2. PMID 15094276.. ...
ന്യുമോണിയ - വിക്കിപീഡിയ
Idiopathic Pulmonary Fibrosis, IPF), അനിയത അന്തരാളകലാ ന്യുമോണിയ (Nonspecific Interstitial Pneumonia, NSIP), ഗുപ്തജന്യ ... An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. Anesthesiology. 2009 ... fibrosis). External agents/. occupational. lung disease. Pneumoconiosis (Asbestosis, Baritosis, Bauxite fibrosis, Berylliosis, ... 16.0 16.1 16.2 16.3 16.4 Simon HB (2005).Infectious Disease:XX:Pneumonia and Other Pulmonary Infections.in David C. Dale, ...
咽炎 - 维基百科，自由的百科全书
特發性肺含鐵血黃素沉積症（英语：Idiopathic pulmonary haemosiderosis）（IPH） ... 鐵釩土纖維化（英语：Bauxite fibrosis）. 鈹肺病（英语：Berylliosis）. 類風濕塵肺綜合症（英语：Caplan's syndrome）. 石末肺（英语：Chalicosis）. 煤礦工人肺塵病（英语：Coalworker's ... Nursing Assistant: A Nursing Process Approach - Basics. Cengage Learning. 2009: 45. ISBN 9781111780500. （原始内容存档于2017-09-08） （英语 ... 滑石肺（
Complex regional pain syndrome
Idiopathic pain syndromes. Local. Complex regional pain syndrome/Reflex sympathetic dystrophy. Generalized. Fibromyalgia. ... Investigators are studying new approaches to treat CRPS and intervene more aggressively after traumatic injury to lower the ... Hypertrophic pulmonary osteoarthropathy. *Nonossifying fibroma. *Pseudarthrosis. *Stress fracture. *Fibrous dysplasia * ... Treatment involves a multidisciplinary approach involving medications, physical and occupational therapy, psychological ...
Idiopathic pulmonary fibrosis. *Sarcoidosis. Obstructive or. restrictive. Pneumonia/. pneumonitis. By pathogen. *Viral ... and diagnostic approach". Journal of investigational allergology & clinical immunology. 20 (5): 364-71; quiz 2 p following 371 ... fibrosis). External agents/. occupational. lung disease. Pneumoconiosis Asbestosis. Baritosis. Bauxite fibrosis. Berylliosis. ... rhinitis includes idiopathic, hormonal, atrophic, occupational, and gustatory rhinitis, as well as rhinitis medicamentosa (drug ...
Thiessen, N. R.; Bremner, R. (2010). "The solitary pulmonary nodule: Approach for a general surgeon". The Surgical Clinics of ... fibrosis). External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. ... A lung nodule or pulmonary nodule is a relatively small focal density in the lung. A solitary pulmonary nodule (SPN) or coin ... The solitary pulmonary nodule". N. Engl. J. Med. 348 (25): 2535-42. doi:10.1056/NEJMcp012290. PMID 12815140.. CS1 maint: ...
瀰漫性泛細支氣管炎 - 维基百科，自由
特發性肺含鐵血黃素沉積症（英语：Idiopathic pulmonary haemosiderosis）（IPH） ... 鐵釩土纖維化（英语：Bauxite fibrosis）. 鈹肺病（英语：Berylliosis）. 類風濕塵肺綜合症（英语：Caplan's syndrome）. 石末肺（英语：Chalicosis）. 煤礦工人肺塵病（英语：Coalworker's ... Ryu, J. H. Classification and approach to bronchiolar diseases. Current Opinion in Pulmonary Medicine. Mar 2006, 12 (2): 145- ... 滑石肺（英语：Pulmonary talcosis）. 綿
In general, idiopathic ventricular tachycardia occurs in younger individuals diagnosed with VT. While the causes of idiopathic ... Brugada P, Brugada J, Mont L, Smeets J, Andries EW (May 1991). "A new approach to the differential diagnosis of a regular ... This is known as idiopathic ventricular tachycardia and in the monomorphic form coincides with little or no increased risk of ...
... cardiac disease due to cardiac fibrosis and restrictive cardiomyopathy; pulmonary airway and parenchymal disease; eosinophilic ... 2003). "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic ... 2006). "A probability-based approach for high-throughput protein phosphorylation analysis and site localization". Nat. ... 2003). "Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome". Proc. Natl. Acad. Sci. U.S.A. ...
Systemic blood flow is diverted to pulmonary flow, elevating pressures in the pulmonary venous system, and promoting leaks of ... Avitabile, CM; Goldberg, DJ; Dodds, K; Dori, Y; Ravishankar, C; Rychik, J (2014). "A multifaceted approach to the management of ... El Mouhadi, S; Taillé, C; Cazes, A; Arrivé, L (2015). "Plastic bronchitis related to idiopathic thoracic lymphangiectasia. ... cystic fibrosis, tuberculosis, pneumonia, and bronchocentric granulomatosis Disorders of lymphatic drainage: lymphangiectasia, ...
Exposure to carbon monoxide or polluted ozone exposure can also lead to cardiac defects of the ventrical septal, pulmonary ... Syphilis causes congenital deafness, mental retardation, and diffuse fibrosis in organs, such as the liver and lungs, if the ... Malformative syndrome ICD-10 Chapter Q: Congenital malformations, deformations and chromosomal abnormalities Idiopathic List of ... systemic-evolutionary approach). In: Mathematical treatment of medical-biological information. M., Nauka, p. 170-181. Montagu A ...
Updated approach for diagnosis of idiopathic pulmonary fibrosis | Univadis
Updated approach for diagnosis of idiopathic pulmonary fibrosis. * elsevier_the_lancet_pneumology_jp_review ... This Review provides an updated approach to the diagnosis of idiopathic pulmonary fibrosis (IPF), based on a systematic search ... Necrotising pancreatitis: is endoscopic step-up approach better than surgical step-up approach?. ... Necrotising pancreatitis: is endoscopic step-up approach better than surgical step-up approach?. ...
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes | European Respiratory Society
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. *Vincent Cottin⇓ ... Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504. ... Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999; 159: ... Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-363. ...
Integrating systems biology approach in idiopathic pulmonary fibrosis research, Barcelona 2016
Yale-led study provides roadmap to discover new treatment for idiopathic pulmonary fibrosis
A Yale-led collaborative study boosts scientific understanding of how the lung disease idiopathic pulmonary fibrosis (IPF) ... Using this approach, they made three key findings. First, they discovered that what looked like normal tissue in the diseased ... Idiopathic Pulmonary Fibrosis, Lung Disease, Lungs, Medical School, Medicine, Pulmonary Fibrosis, Research, RNA, RNA Sequencing ... Yale-led study provides roadmap to discover new treatment for idiopathic pulmonary fibrosis. *Download PDF Copy ...
UA researchers receive $4.4 million grant to focus on idiopathic pulmonary fibrosis
Applying a Proteomics-based Approach to the Clinic. Professor Matthias Mann. Matthias Mann explains why applying proteomics- ... Idiopathic Pulmonary Fibrosis, Knee, Lung Disease, Lungs, Medicine, Preclinical, Primary Care, Pulmonary Fibrosis, Research, ... "Idiopathic pulmonary fibrosis is a deadly disease with a very grim prognosis," he said. "Dr. Hecker has laid the groundwork for ... Named idiopathic pulmonary fibrosis, the disease is caused by the formation of scar tissue within the lungs. ...
InterMune Buys Out License Agreement for Idiopathic Pulmonary Fibrosis Candidate | GEN - Genetic Engineering and Biotechnology...
Home News InterMune Buys Out License Agreement for Idiopathic Pulmonary Fibrosis Candidate ... "If our Phase III CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis is successful and we register the compound ... InterMune Buys Out License Agreement for Idiopathic Pulmonary Fibrosis Candidate. November 26, 2007. 0 ... Novel Approach Can Determine the Sources of the Guts Microbiome. CRISPR-Cas9 Gene Editing Used to Engineer Primate Model of ...
What is the role of radiography in the workup of idiopathic pulmonary fibrosis (IPF)?
Raghu G. Idiopathic pulmonary fibrosis. A rational clinical approach. Chest. 1987 Jul. 92(1):148-54. [Medline]. ... Idiopathic Pulmonary Fibrosis Imaging Q&A What is the role of radiography in the workup of idiopathic pulmonary fibrosis (IPF)? ... Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J. 2016 May. 47 (5):1445-51. [ ... 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: ...
Idiopathic Pulmonary Fibrosis: Symptoms, Diagnosis, and Treatment
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease that causes scar tissue to grow inside your lungs. Learn more about ... The flexible tube approach is called a bronchoscopy. During the bronchoscopy, a doctor will use fluid to wash out your lungs ... Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis - Idiopathic Pulmonary Fibrosis (IPF) * Pulmonary Fibrosis ... Pulmonary Fibrosis Treatment What Is Idiopathic Pulmonary Fibrosis (IPF)?. Idiopathic pulmonary fibrosis (IPF) is a serious ...
A candidate gene for familial idiopathic pulmonary fibrosis identified
New Approach to Treating Chronic Itch 15.08.2018 , Universität Zürich All articles from Life Sciences ,,,. The most recent ... Idiopathic pulmonary fibrosis (IPF) is a chronic, late-onset disease of lung parenchyma with unknown etiology. IPF has been ... A candidate gene for familial idiopathic pulmonary fibrosis identified. 30.06.2006. ELMOD2-gene is a prime candidate gene for ... familial idiopathic pulmonary fibrosis, suggests the recent study published by the researchers at the University and University ...
Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis | Thorax
Idiopathic pulmonary fibrosis. A rational clinical approach. Chest 1987;92:148-54. ... Idiopathic pulmonary fibrosis (IPF) is the most common and most severe form of idiopathic interstitial pneumonia, with few ... Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.doi:10.1164/rccm.200703-463PP. ... Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-63.doi: ...
Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis and Treatment | Elsevier CME
Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis and Treatment. ... Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis and Treatment. ... Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early ... or management of patients with idiopathic pulmonary fibrosis.. EDUCATIONAL OBJECTIVES Upon completion of this activity, ...
Idiopathic pulmonary fibrosis: diagnosis, management and new therapies
Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made ... Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China Idiopathic pulmonary fibrosis ( ... Treatment of idiopathic pulmonary fibrosis: a network meta-analysis Idiopathic pulmonary fibrosis (IPF) is an interstitial lung ... Idiopathic pulmonary fibrosis: moving forward Idiopathic pulmonary fibrosis (IPF) is the prototype of a large and heterogeneous ...
Characterisation of Reflux and Aspiration in Idiopathic Pulmonary Fibrosis; An Integrated Approach - ePrints - Newcastle...
Idiopathic Pulmonary Fibrosis (IPF)-Market Overview, Clinical Trials, diagnostic trends and Study Period 2017-2028 - Express...
Idiopathic Pulmonary Fibrosis Report Insights. Patient Population. Therapeutic Approaches. Pipeline Analysis. Market Size and ... Idiopathic Pulmonary Fibrosis (IPF) Epidemiology. The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the ... the market of Idiopathic Pulmonary Fibrosis in 8G was found to be USD 1644.4 million in 2017.. Idiopathic Pulmonary Fibrosis ... The Delve Insight Idiopathic Pulmonary Fibrosis market report gives the thorough understanding of the Idiopathic Pulmonary ...
Lung cancer in patients with idiopathic pulmonary fibrosis | European Respiratory Society
Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational ... Lung cancer in patients with idiopathic pulmonary fibrosis. J. Park, D.S. Kim, T.S. Shim, C-M. Lim, Y. Koh, S.D. Lee, W.S. Kim ... Lung cancer in patients with idiopathic pulmonary fibrosis. J. Park, D.S. Kim, T.S. Shim, C-M. Lim, Y. Koh, S.D. Lee, W.S. Kim ... Lung cancer in patients with idiopathic pulmonary fibrosis. J. Park, D.S. Kim, T.S. Shim, C-M. Lim, Y. Koh, S.D. Lee, W.S. Kim ...
Integrative Computational Screening and Systems Biology Approaches Lead to Grant for Potential Idiopathic Pulmonary Fibrosis...
150,000 grant to repurpose Barasertib as a potential treatment for Idiopathic Pulmonary Fibrosis. ... Integrative Computational Screening and Systems Biology Approaches Lead to Grant for Potential Idiopathic Pulmonary Fibrosis ... Integrative Computational Screening and Systems Biology Approaches Lead to Grant for Potential Idiopathic Pulmonary Fibrosis ... Idiopathic Pulmonary Fibrosis (IPF) is an irreversible disease that results in scarring of lung tissue and loss of lung ...
Potential drug target discovered for idiopathic pulmonary fibrosis | FierceBiotech
... have shown that levels of a protein called FK506-binding protein 10 are elevated in patients with idiopathic pulmonary fibrosis ... These approaches are best developed in international networks.. Staab-Weijnitz sees the work having broad implications. ... are elevated in patients with idiopathic pulmonary fibrosis (IPF).. IPF is a chronic disease affecting the connective tissue ... IPF is characterized by fibrosis, the formation of scar tissue that builds up in the lungs and progressively impairs lung ...
Frontiers | Glutamyl-Prolyl-tRNA Synthetase Regulates Epithelial Expression of Mesenchymal Markers and Extracellular Matrix...
Glutamyl-prolyl-tRNA-synthetase (EPRS) has been identified as a target for anti-fibrosis therapy, but the link between EPRS and ... Glutamyl-prolyl-tRNA-synthetase (EPRS) has been identified as a target for anti-fibrosis therapy, but the link between EPRS and ... Idiopathic pulmonary fibrosis (IPF), a chronic disease of unknown cause, is characterized by abnormal accumulation of ... Idiopathic pulmonary fibrosis (IPF), a chronic disease of unknown cause, is characterized by abnormal accumulation of ...
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK | Thorax
Report on problems, research approaches, needs. 73-432. Washington, DC: DHEW, 1972. ... Idiopathic pulmonary fibrosis. Overall, the crude incidence rate for IPF was 4.6 (95% CI 4.3 to 4.9) per 100 000 person-years, ... Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respirat Crit Care ... Background: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but ...
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis,...
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, ... Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, ... Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, ...
Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients - Full Text View -...
Drug therapy usually is ineffective approach, what makes a call for an effective treatment. ... Fibrosis. Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis. Idiopathic Interstitial Pneumonias. Pathologic Processes. Lung ... Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients. The safety and scientific ... Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients. Study Start Date :. January ...
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis | PPA
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although the precise cause of the disease ... recent studies have shown that the pathogenesis of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of ... Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis Yoshito Takeda,1 Kazuyuki Tsujino,2 Takashi Kijima,1 ... Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs ...
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation? | European Respiratory Society
Not only has this approach proven ineffective, but also harmful. Recently, the National Heart, Lung, and Blood Institute ( ... Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?. Spyros A. Papiris, Konstantinos ... Clinical review: idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadnes thread. Crit Care 2010; 14: 246. ... Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9: 129-140. ...
Role of Transbronchial Lung Cryobiopsies in Diffuse Parenchymal Lung Diseases: Interest of a Sequential Approach
The journal encourages submissions on pulmonology, respiratory medicine, thoracic surgery, lung diseases, pulmonary function ... diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and ... Pulmonary Medicine is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and ... G. Raghu, H. R. Collard, J. J. Egan et al., "An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence- ...
Impact of COVID-19 on the Idiopathic Pulmonary Fibrosis Global Market to 2029
Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a ... Key Topics Covered: 1 Table of Contents1.1 List of Tables1.2 List of Figures2 Idiopathic Pulmonary Fibrosis: Executive ... Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no ... 18, 2020 (GLOBE NEWSWIRE) -- The Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 report has been ...
Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient. - PubMed - NCBI
Management of IPF requires an orderly approach, with regular evaluations and implementation of both pharmacological and ... Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal form of diffuse interstitial lung disease. ... Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient.. Egan JJ1. ... Pulmonary rehabilitation can relieve patients from the distressing symptoms of IPF and improve quality of life. Oxygen therapy ...
Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made...
Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made ... This is true even for evidence-based guidelines that focus on complex and rare diseases such as idiopathic pulmonary fibrosis ( ... Evidence-basedGuidelineIdiopathic pulmonary fibrosis. Background. Evidence-based guidelines have undergone intense evolution ... Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and ...
REVISED: NEW EXPANDED ACCESS PROGRAM ANNOUNCED FOR IDIOPATHIC PULMONARY FIBROSIS PATIENTS
The Coalition for Pulmonary Fibrosis (CPF) is alerting the Pulmonary Fibrosis (PF) community throughout the US to a new ... for an investigational therapy for Idiopathic Pulmonary Fibrosis (IPF). The launch of Boehringer Ingelheims EAP for Nintedanib ... The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive ... About Pulmonary Fibrosis (PF). Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as ...
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50...
... versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Patients who completed the INPULSIS® trials could receive ... Current approaches to the management of idiopathic pulmonary fibrosis.. *Ganesh Raghu, Luca Richeldi ... Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. *Lutz Wollin, Eva Wex, +4 authors Martin Kolb ... Idiopathic pulmonary fibrosis: pathogenesis and management. *Giacomo Sgalla, Bruno Iovene, Mariarosaria Calvello, Margherita ...
Harari S[au] - PubMed - NCBI
Severe idiopathic pulmonary fibrosis: A clinical approach.. Lipsi R, Mazzola D, Caminati A, Elia D, Lonati C, Harari S. ... Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A ... Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.. Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, ... Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care. ...
DiagnosisPatientsPneumoniaCoalition for Pulmonary Fibrosis2017HypertensionInterstitial lungIntroduction IdiopathicManagement of idiopathic pulmonarExacerbation of Idiopathic PulmonarTreat idiopathic pulmonarComorbiditiesInflammation and fibrosisBleomycin-induced pulmonary fibrosisPrognosisPathogenesis of pulmonary fibrosisBone Marrow FailureFibrotic diseaseTherapeutic approachFamilial pulmonary fibrosisBiomarkersEmphysemaTreatment of pulmonary fibrosisLung parenchymaAntifibroticCritical Care MedEpithelial to Mesenchymal TransitionSymptomsTherapiesGeneticsNintedanibResearchClinical trialsRicheldiCryptogenicMortalityEpidemiologyChronic fibrosing inRespiratoryDisordersDivision of Pulmonary MedicineDisorder characterized
- A multidisciplinary approach in the field of interstitial lung disease with NSIP, also including rheumatologic expertise, is fundamental to achieve a prompt and correct diagnosis. (biomedcentral.com)
- Semi-quantitative imaging, including color-coded images (HU related), is a new and promising approach in the field of ILD diagnosis and prognosis. (springeropen.com)
- Honeycombing is a feature of established fibrosis and is considered as an important criterion when diagnosing UIP and IPF, although recent evidence suggests that honeycombing may not be required for an HRCT-based diagnosis of IPF in selected patients. (springeropen.com)
- The study involved 50 patients diagnosed as idiopathic interstitial pneumonia. (springeropen.com)
- Advances in HRCT scanning and interpretation have facilitated and improved accuracy for use in diagnosing idiopathic pulmonary fibrosis (IPF), eliminating the need for a surgical biopsy in many patients. (springeropen.com)
- The extent of honeycombing and reticulation has been used as a predictor of mortality in patients with idiopathic pulmonary fibrosis (IPF) [ 9 ]. (springeropen.com)
Coalition for Pulmonary Fibrosis9
- CULVER CITY, Calif., June 27, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) is alerting the Pulmonary Fibrosis (PF) community throughout the US to a new Expanded Access Program (EAP) for an investigational therapy for Idiopathic Pulmonary Fibrosis (IPF). (globenewswire.com)
- However," Ms. Barnes, who is vice president of patient outreach and advocacy at the Coalition for Pulmonary Fibrosis added, "every physician when communicating with a patient with IPF must be prepared to spend as much time needed to help patients understand the uncertainties and potential consequences of a treatment regimen, especially those with a weak recommendation. (medindia.net)
- This education piece will be posted on the ATS Web site (www.thoracic.org), as well as the Web site of the Coalition for Pulmonary Fibrosis (www.coalitionforpf.org), an ATS Public Advisory Roundtable member organization, whose focus is on research, advocacy, support and education for the pulmonary fibrosis community. (medindia.net)
- CULVER CITY, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) launched a pilot program with the Genetic Alliance to insure patients, their caregivers and families are heard by the U.S. Food & Drug Administration. (cnbc.com)
- As it reviews possible first drugs for the indication of IPF later this year, the FDA will need to better understand these patients, their experiences, and the level of their willingness to accept risk," said Mishka Michon, CEO of the Coalition for Pulmonary Fibrosis. (cnbc.com)
- WASHINGTON, July 12, 2011 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act (PFREA) has been introduced in the Senate by Senators Chris Coons (D-DE) and Mike Crapo (R-ID) in the U.S. House of Representatives by Rep. Erik Paulsen (R-MN) and Rep. Tammy Baldwin (D-WI). (redorbit.com)
- CULVER CITY, Calif., July 25, 2011 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) proudly announces the winners of its three annual awards for distinguished service. (redorbit.com)
- Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Commitment to Pulmonary Fibrosi. (bio-medicine.org)
- SAN JOSE, Calif. , Feb. 25 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) and the American Thoracic Society (ATS), the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to fund Pulmonary Fibrosis (PF) research. (bio-medicine.org)
- The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis from 2017 to 2028 segmented by eight major markets. (express-press-release.net)
- The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent diagnosed cases, severity-specific prevalent cases and gender and age -specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Canada, and Japan from 2017-2028. (express-press-release.net)
- According to Delve Insight, total prevalent population of Idiopathic Pulmonary Fibrosis (IPF) in G8 markets was found to be 229,170 in 2017. (express-press-release.net)
- GlobalDatas pharmaceutical and healthcare report, Idiopathic Pulmonary Fibrosis Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. (researchmoz.us)
- Annualized global idiopathic pulmonary fibrosis market revenues data from 2001 to 2009, forecast forward for eight years to 2017. (researchmoz.us)
- In advanced stages, there is radiographic evidence of pulmonary arterial hypertension. (medscape.com)
- Pulmonary hypertension and chronic lung disease: where are we headed? (nih.gov)
- We present evidence for the role of co-occurring disorders (i.e., gastroesophageal reflux disease, pulmonary hypertension, cardiovascular disease, osteoporosis, infectious agents, and other genetic factors) on the severity of the progression of human IPF disease. (springer.com)
- Interests: Biomarkers of pulmonary hypertension and brain. (hopkinsmedicine.org)
- In addition, the presence of comorbidities and complications such as emphysema, pulmonary hypertension, cardiovascular diseases and bronchogenic carcinoma are clinical factors that also have been associated with more rapid progression of IPF. (mdpi.com)
- Acute pulmonary hypertension increases RV afterload and causes acute cor pulmonale which is associated with high mortality rates [ 5 ]. (hindawi.com)
- Imaging of idiopathic interstitial lung diseases. (medscape.com)
- Raghu G. Interstitial lung disease: a diagnostic approach. (medscape.com)
- Idiopathic pulmonary fibrosis (IPF) is the most common and most deadly type of interstitial lung disease. (biomedcentral.com)
- Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic interstitial lung disease with a relentlessly progressive course and fatal outcome. (biomedcentral.com)
- Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with high morbidity and mortality. (biomedcentral.com)
- Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). (yahoo.com)
- Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal form of diffuse interstitial lung disease. (nih.gov)
- Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the only interstitial lung disease for which approved pharmacological treatments are available. (biomedcentral.com)
- Approach to the adult with interstitial lung disease: Clinical evaluation. (mayoclinic.org)
- Background Idiopathic pulmonary fibrosis is a progressive interstitial lung disease, which ultimately leads to respiratory failure and death. (centerwatch.com)
- Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause, is the most common and deadly of the idiopathic interstitial pneumonias. (mdpi.com)
- The guest editors for this issue, Talmadge King, Harold Collard, celebrated pulmonary specialists from UCSF, and Luca Richeldi, renowned visiting professor to UCSF from University of Modena, Italy, bring together a state-of-the-art issue on the important topic of Interstitial Lung Diseases (ILD). (elsevier.com)
- Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History. (medicalcriteria.com)
- IP lies in the center of a heterogenous group of diffuse interstitial lung diseases (ILDs), either idiopathic or linked to underlying disorders. (intechopen.com)
- IP is included in the "interstitial lung disease" (ILD), i.e., a heterogenous group of diffuse parenchymal lung disorders, either idiopathic or associated with injurious or inflammatory causes, in which the major site of damage is the lung interstitium [ 3 ]. (intechopen.com)
- Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition, progressive. (eur.nl)
- Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis, which is characterised by destruction of normal lung architecture and excessive deposition of lung extracellular matrix. (ersjournals.com)
- Some forms of interstitial lung disease, particularly idiopathic pulmonary fibrosis, which has no known cause, have a very high death rate due to respiratory failure. (rxpgnews.com)
- Because it can be difficult to obtain lung biopsy samples for some types of interstitial lung disease, the Simmons Center investigators collaborated with researchers in Mexico to obtain samples for another type of pulmonary fibrosis known as hypersensitivity pneumonitis - a pneumonia-like inflammation of the lungs caused by the body's immune reaction to small air-borne particles that is more prevalent in countries such as Mexico where pet birds are common. (rxpgnews.com)
- Interstitial lung diseases (ILD) are a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial and vascular spaces. (appliedradiology.com)
- Pulmonary Fibrosis is a form of interstitial lung disease (ILD) that causes inflammation and eventual scarring (fibrosis) in place of normal healthy lung tissue. (piedmont.org)
Management of idiopathic pulmonar4
- Kishaba T. Practical management of Idiopathic Pulmonary Fibrosis. (medscape.com)
- Current approaches to the management of idiopathic pulmonary fibrosis. (semanticscholar.org)
- New official clinical guidelines on the diagnosis and management of idiopathic pulmonary fibrosis (IPF) have been issued by the American Thoracic Society. (medindia.net)
- This quality standard covers the diagnosis and management of idiopathic pulmonary fibrosis in adults, from the initial suspicion of the disease to referral, supportive care and treatment. (nice.org.uk)
Exacerbation of Idiopathic Pulmonar2
- Approach to acute exacerbation of idiopathic pulmonary fibrosis.Ann Thorac Med. (gpnotebook.com)
- Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an often deadly complication of IPF. (medworm.com)
Treat idiopathic pulmonar2
- Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. (nih.gov)
- Idiopathic pulmonary fibrosis: Effects and optimal management of comorbidities. (mayoclinic.org)
- Idiopathic pulmonary fibrosis is discussed, including phenotypes and comorbidities, acute exacerbation and accelerated decline, management, and pathobiology of novel approaches to therapy. (elsevier.com)
Inflammation and fibrosis3
- Idiopathic pulmonary fibrosis (IPF) is a chronic disease causing inflammation and fibrosis (scarring) of tissue in the lungs. (uvahealth.com)
- Interstitial pneumonia (IP) refers to involvement of the lung parenchyma by varying degrees of inflammation and fibrosis, in contrast to airspace disease typically seen in bacterial pneumonia. (intechopen.com)
- The latter is characterized by inflammation and fibrosis that occurs suddenly and progresses rapidly over a relatively short period of time. (rxpgnews.com)
Bleomycin-induced pulmonary fibrosis1
- Idiopathic pulmonary fibrosis is a deadly disease with a very grim prognosis," he said. (news-medical.net)
- Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. (yahoo.com)
- Idiopathic pulmonary fibrosis is defined as a chronic fibrosing interstitial pneumonia limited to the lung, of unknown cause, with poor prognosis and few treatment options. (archbronconeumol.org)
- Develop biomarkers using proteomic and genomic approaches that will facilitate establishing the diagnosis and prognosis of both familial and sporadic forms of idiopathic interstitial pneumonia (IIP). (clinicaltrials.gov)
- Prognosis of idiopathic pulmonary fibrosis is worse than nonspecific interstitial pneumonia and other idiopathic interstitial pneumonias. (ersjournals.com)
- Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma, associated with significant morbidity and poor prognosis. (biomedcentral.com)
- The landscape of Idiopathic Pulmonary Fibrosis (IPF), a chronic interstitial pneumonia characterized by the invariably progressive deposition of fibrotic tissue in the lungs and overall poor prognosis, has been revolutionized over the last decades by substantial advances in the understanding of disease pathobiology, the standardization of the diagnostic processes and the availability of the first treatments that modify the disease course. (biomedcentral.com)
Pathogenesis of pulmonary fibrosis2
- Although the precise cause of the disease is still unknown, recent studies have shown that the pathogenesis of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of alveolar epithelial cells considered a primary event. (dovepress.com)
- Melissa Hunter Piper, Ph.D. at the Davis Heart and Lung Research Institute at Ohio State University who studied whether the loss of the expression of miR-17-92 (microRNA) cluster contributes to the pathogenesis of pulmonary fibrosis. (bio-medicine.org)
Bone Marrow Failure2
- These disorders include individuals with cancer, bone marrow failure/aplastic anemia, lung disease including idiopathic pulmonary fibrosis and liver cirrhosis, among others. (hopkinsmedicine.org)
- Recently, short telomeres have been linked to the etiology of degenerative diseases such as idiopathic pulmonary fibrosis, bone marrow failure, and cryptogenic liver cirrhosis. (jci.org)
- At present, therapeutic approach of IPF involves both non-pharmacological and pharmacological strategies. (express-press-release.net)
- The therapeutic approach in idiopathic pulmonary fibrosis has changed substantially over the past 5 years. (archbronconeumol.org)
- Inhibition of dimethylarginine dimethylaminohydrolase enzyme in lung attenuates two hallmarks of pulmonary fibrosis, excess cells and excess collagen, thereby offering a therapeutic approach. (sciencemag.org)
Familial pulmonary fibrosis3
- The rs35705950 single-nucleotide polymorphism (SNP)-a promoter site of an airway mucin gene ( MUC5B )-is strongly associated with IPF and familial pulmonary fibrosis and not seen in other secondary causes of lung fibrosis. (radiopaedia.org)
- The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. (clinicaltrials.gov)
- Familial Pulmonary Fibrosis (FPF) is a sub-category of the idiopathic interstitial pneumonias (IIPs). (clinicaltrials.gov)
Treatment of pulmonary fibrosis2
- Idiopathic pulmonary fibrosis (IPF) is a chronic, late-onset disease of lung parenchyma with unknown etiology. (innovations-report.com)
- We further demonstrate that pleural fibrosis can expand into the lung parenchyma from the visceral layer, but not into the muscle from the parietal layer. (jimmunol.org)
Critical Care Med4
- Dr. Robert C. Hyzy is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Michigan in Ann Arbor. (springer.com)
- Dr. Hyzy completed his residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at the University of Michigan. (springer.com)
- One of the challenges is to know whether a blood protein actually reflects the situation in the lung," notes Thomas J. Richards, Ph.D., study co-first author and research assistant professor in the Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine. (innovations-report.com)
- In an article in the Jan. 15 issue of the American Journal of Respiratory Critical Care Medicine, University of Pittsburgh researchers report that a serious, life-threatening form of pulmonary fibrosis, called idiopathic pulmonary fibrosis, lacks all the hallmarks of inflammation and is probably unnecessarily treated with anti-inflammatory drugs. (rxpgnews.com)
Epithelial to Mesenchymal Transition2
- The present study investigated the effects of iPS cells on inflammatory responses, transforming growth factor (TGF)-β1 signaling pathway, and epithelial to mesenchymal transition (EMT) during bleomycin (BLM)-induced lung fibrosis. (frontiersin.org)
- Harikrishna Tanjore , Ph.D. in the Center for Lung Research at Vanderbilt University Medical Center: The study's purpose was to determine the extent to which epithelial to mesenchymal transition (EMT) contributes to lung fibrosis and to investigate the role of TGF-beta in EMT in the lungs. (bio-medicine.org)
- You can have idiopathic pulmonary fibrosis for a long time without noticing any symptoms. (webmd.com)
- The Delve Insight Idiopathic Pulmonary Fibrosis market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, staging, symptoms, pathophysiology, and diagnostic trends. (express-press-release.net)
- Most people with idiopathic pulmonary fibrosis have symptoms of breathlessness, which may at first occur only on exertion, and cough, with or without sputum. (nice.org.uk)
- Pulmonary fibrosis is a medical condition that greatly affects and impairs the respiratory system, causing dyspnea (shortness of breath), chronic coughing, fatigue and other symptoms. (yahoo.com)
- New therapies that inhibit fibroblast activation to reverse established and ongoing fibrosis would improve the current standard of care for IPF. (cincyinformatix.org)
- Idiopathic interstitial pneumonias (IIPs) have a progressive and often fatal course, and their enigmatic etiology has complicated approaches to effective therapies. (pnas.org)
- Annually 40,000 individuals die in the United States from pulmonary fibrosis and there are no FDA-approved therapies. (yahoo.com)
- However, InterMune Inc. currently has an idiopathic pulmonary fibrosis drug, Pirfenidone, in Phase III trials within the United States and, like several other therapies, is available in EU member states. (yahoo.com)
- This article collection in BMC Medicine seeks to address the rapidly changing landscape in the field of IPF, by highlighting genetics, biomarker discovery, diagnostic approaches, clinical management, novel treatments, guidelines and regulatory issues. (biomedcentral.com)
- The goal of research in our lab is to understand the genetics and pathophysiology of telomere-mediated disorders in hopes of delineating translational approaches to their treatment. (hopkinsmedicine.org)
- These disorders have recognizable clinical manifestations, and the telomere defect explains their genetics and informs the approach to their treatment. (jci.org)
- Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. (semanticscholar.org)
- Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. (semanticscholar.org)
- Nintedanib, marketed under the brand names Ofev and Vargatef, is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for some types of non-small-cell lung cancer. (wikipedia.org)
- Nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). (wikipedia.org)
- Nintedanib targets growth factor receptors, which have been shown to be involved in the mechanisms by which pulmonary fibrosis occurs. (wikipedia.org)
- Albany, US, 2019-Jul-19 - /EPR Network/ -Market Research Hub (MRH) has actively included a new research study titled " Idiopathic Pulmonary Fibrosis (IPF)-Market Insights, Epidemiology and Market " Forecast-2028 to its wide online repository. (express-press-release.net)
- A research team at Cincinnati Children's Hospital Medical Center has received a $150,000 grant to repurpose Barasertib as a potential treatment for Idiopathic Pulmonary Fibrosis. (cincyinformatix.org)
- The Jegga and Madala research team found that Aurora Kinase B (AURKB) functions as a positive regulator of pulmonary fibrosis, causing excessive proliferation and survival in fibroblasts. (cincyinformatix.org)
- As the idiopathic pulmonary fibrosis (IPF) community enters a new era of clinical research activity we consider that there is greater capacity for patient involvement and partnership.Patient involvement in research can be optimised through collaborations in the research design, study conduct, and dissemination. (nih.gov)
- It is time to refocus on a patient-centred approach with regards to the co-investigator role, PRO development, and research participants. (nih.gov)
- Researchers at Helmholtz Zentrum München, a partner in the German Center for Lung Research, have discovered a new mechanism of action of two drugs used in the treatment of idiopathic pulmonary fibrosis (IPF). (helmholtz-muenchen.de)
- The Helmholtz Zentrum München , the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. (helmholtz-muenchen.de)
- Genetic Alliance and the Pharmaceutical Research and Manufacturers of America (PhRMA) developed the initiative to explore the use of a technology-enabled, crowd-sourcing approach to patient engagement as a complement to ongoing patient-focused drug development efforts under the Prescription Drug User Fee Act (PDUFA V). (cnbc.com)
- First, they inform clinical practice, where the diagnostic approach needs to be standardised based on the most up-to-date evidence generated by clinical research. (ersjournals.com)
- SCOTTSDALE, AZ--(Marketwired - Aug 21, 2014) - New Amsterdam Sciences (NAS), an emerging bioscience company, announced today that while advancing to phase1 clinical trials it will continue its commitment for further research with renowned biochemist and research scientist Dr. Jacob Finkelstein of the University of Rochester Medical Center to advance initiatives for treatments of idiopathic pulmonary fibrosis (IPF). (yahoo.com)
- New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911B is the company's lead compound, and is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, wound healing and solid tumors. (yahoo.com)
- Our investigational research and clinical trials affords us the ability to discover new approaches to pulmonary fibrosis and the chance to offer you the latest treatments available. (uvahealth.com)
- Get a glimpse of the medical horizon: Find out more about our current research in pulmonary fibrosis . (uvahealth.com)
- There is no known cause and no FDA-approved treatments for pulmonary fibrosis, yet research funding has remained stagnant," Senator Crapo said. (redorbit.com)
- Each honoree has contributed in a significant way to the effort to fight Pulmonary Fibrosis (PF) - in research, humanitarian and advocacy efforts. (redorbit.com)
- This discovery not only identifies a major risk factor for pulmonary fibrosis, but also points us in an entirely new direction for research into the causes and potential treatments for this difficult disease," said Max Seibold, PhD, first author and research instructor at National Jewish Health and the Center for Genes, Environment and Health. (nationaljewish.org)
- The research also demonstrates how a genetic approach to disease can uncover a previously unknown and unsuspected association disease. (nationaljewish.org)
- Research into pulmonary fibrosis has been quite difficult. (nationaljewish.org)
- This research suggests that mucus production where the small airways and the air sacs converge may play a significant role in pulmonary fibrosis," said senior author David Schwartz, MD, Chair of the Department of Medicine at the University of Colorado School of Medicine and Director of the Center for Genes, Environment and Health at National Jewish Health. (nationaljewish.org)
- Lung Foundation Australia is proud to be a founding partner of the Centre for Research Excellence - Pulmonary Fibrosis (CRE-PF), a comprehensive and integrated clinical research program that aims to change the approach to Pulmonary Fibrosis (PF) care and treatment in Australia. (lungfoundation.com.au)
- Our ability to deliver Idiopathic Pulmonary Fibrosis research relies on the generosity and support of organisations and individual donors. (lungfoundation.com.au)
- The CPF and the Pulmonary Fibrosis Foundation (PFF) will each commit $200,000 to co-fund four two-year research grants and the ATS will provide management of the grants. (bio-medicine.org)
- Through our partnership with the CPF, we are able to advance the careers of young investigators conducting groundbreaking research in Pulmonary Fibrosis. (bio-medicine.org)
- Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. (semanticscholar.org)
- Nordic Bioscience has over 25 years' experience in biomarker development and clinical trials with extensive expertise in rheumatology and fibrosis. (bms.com)
- The company has more than 25 years' experience in biomarker development and clinical trials and has acquired extensive expertise in rheumatology and fibrosis. (bms.com)
- The clustering of cryptogenic liver cirrhosis with IPF suggests that the telomere shortening we identify has consequences and can contribute to what appears clinically as idiopathic progressive organ failure in the lung and the liver. (pnas.org)
- Idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis) is specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. (uptodate.com)
- Cryptogenic fibrosing alveolitis (CFA) (or idiopathic pulmonary fibrosis) is a disease of unknown aetiology which is characterised initially by a cellular alveolar infiltrate and later by fibrosis of the alveolar walls. (gpnotebook.com)
- Pulmonary fibrosis is a progressive and irreversible fibrotic lung disorder with high mortality and few treatment options. (frontiersin.org)
- Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. (cdc.gov)
- We analyzed mortality data using ICD-10 code J84.1-"Other interstitial pulmonary diseases with fibrosis," derived age-adjusted mortality rates for 1999-2003, and assessed occupational risks for 1999, by calculating proportionate mortality ratios (PMRs) and mortality odds ratios (MORs) using a matched case-control approach. (cdc.gov)
- Pleural fibrosis is a misunderstood disorder which can cause severe restrictive lung disease with high morbidity and even mortality. (jimmunol.org)
- Depending on disease severity, pleural fibrosis can compromise respiratory function, markedly impair quality of life, and can be associated with high morbidity or even mortality. (jimmunol.org)
- Today, IP represents the most critical pulmonary complication in CTD, resulting in significant morbidity and mortality. (intechopen.com)
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality rate and limited treatment possibilities. (ersjournals.com)
- and idiopathic pulmonary fibrosis (IPF), a progressive lung disease with a high mortality rate. (bms.com)
- A high level of suspicion is necessary, however, as most pulmonary drug toxicities are associated with significant morbidity and mortality. (appliedradiology.com)
- DelveInsights Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, Canada, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. (express-press-release.net)
- The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every eight major countries. (express-press-release.net)
- Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care. (nih.gov)
Chronic fibrosing in1
- Background/Aims -The pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), a chronic and incurable human respiratory disease, is not well established. (bmj.com)
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. (springer.com)
- These pathologic changes result in progressive decline in pulmonary function, eventually leading to respiratory failure ( Wynn, 2011 ). (frontiersin.org)
- Two guidance documents for the diagnosis of idiopathic pulmonary fibrosis (IPF) have been recently published by international experts representing major respiratory and radiological societies [ 1 , 2 ]. (ersjournals.com)
- Primarily, IP refers to the particular disease entities which belong to idiopathic interstitial pneumonia (IIP) defined by the 2002 and 2012 American Thoracic Society/European Respiratory Society (ATS/ERS) classification [ 1 - 4 ]. (intechopen.com)
- Some of these features are due to chronic hypoxemia (oxygen deficiency in the blood), are not specific for IPF, and can occur in other pulmonary disorders. (wikipedia.org)
- One of the primary disorders classified as ILD is idiopathic pulmonary fibrosis (IPF), a fatal disorder characterized by the continued decline in lung function. (springer.com)
- At UVA, our experience in the rare and complex disorders that constitute pulmonary fibrosis means that we can develop an approach to your unique condition with accuracy and precision. (uvahealth.com)
Division of Pulmonary Medicine1
- Using a computational drug discovery pipeline coupled with preclinical validation studies, Anil Jegga , DVM, MRes, of the Division of Biomedical Informatics, and Satish Madala , PhD, of the Division of Pulmonary Medicine, identified aurora kinase B (AURKB) as a lead target and AURKB-selective inhibitor Barasertib as a lead small molecule for IPF. (cincyinformatix.org)
- Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis - and deterioration of the lungs, which slowly robs its victims of their ability to breathe. (globenewswire.com)
- Idiopathic pulmonary fibrosis (IPF) identifies a specific lung disorder characterized by chronic, progressive fibrosing interstitial pneumonia of unknown etiology, which lacks effective treatment. (biomedcentral.com)